PYXS — Pyxis Oncology Income Statement
0.000.00%
Last trade - 00:00- $78.05m
- -$48.78m
- $16.15m
Annual income statement for Pyxis Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 16.1 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 15.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.9 | 69.7 | 123 | 82.2 | 106 |
| Operating Profit | -12.9 | -69.7 | -123 | -82.2 | -89.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.8 | -76 | -121 | -73.8 | -79.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12.8 | -76 | -121 | -73.8 | -77.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.8 | -76 | -121 | -73.8 | -77.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.8 | -76 | -121 | -73.8 | -77.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.392 | -2.36 | -3.65 | -1.85 | -1.09 |
| Dividends per Share |